Does valganciclovir hydrochloride (Valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?

Transplantation Proceedings

Volumn 37, Issue 7, 2005, Pages 3182-3186

  Jain, A ^a,b   Orloff, M ^a   Kashyap, R ^a   Lansing, K ^a   Betts, R ^a   Mohanka, R ^a   Menegus, M ^a   Ryan, C ^a   Bozorgzadeh, A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Box SURG ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEATH; DISEASE COURSE; DONOR; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY FUNCTION; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; SEROLOGY; SYMPTOM; TIME; TREATMENT FAILURE; VIRUS HEPATITIS;

ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BIOPSY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNOGLOBULIN G; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 26444437323     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.07.032     Document Type: Article

References (24)

1. D. Mutimer CMV infection of transplant recipients J Hepatol 25 1996 259
2. R.H. Wiesner, E. Marin, M.K. Porayko Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation Gastroenterol Clin North Am 22 1993 351
3. C.V. Paya, J.A. Wilson, M.J. Espy Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients a randomized, placebo-controlled trial J Infect Dis 185 2002 854
4. J.K. McGavin, K.L. Goa Ganciclovir an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients Drugs 61 2001 1153
5. S. Noble, D. Faulds Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients Drugs 56 1998 115
6. A.D. Badley, E.C. Seaberg, M.K. Porayko Prophylaxis of cytomegalovirus infection in liver transplantation a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database Transplantation 64 1997 66
7. E. Gane, F. Saliba, G.J. Valdecasas The Oral Ganciclovir International Transplantation Study Group Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients [corrected] Lancet 350 1997 1729 Erratum in: Lancet 351:454, 1998
8. N. Singh, V.L. Yu, L. Mieles High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial Ann Intern Med 120 1994 375
9. N. Turgeon, J.A. Fishman, N. Basgoz Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy Transplantation 66 1998 1780
10. A.C. Koetz, R. Delbruck, A. Furtwangler Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients a prospective, double-blind, placebo-controlled study Transplantation 72 2001 1325
11. D.J. Winston, R.W. Busuttil Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus- seropositive liver transplant recipients Transplantation 75 2003 229
12. R.H. Rubin, S.A. Kemmerly, D. Conti Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis Transpl Infect Dis. 2 2000 112
13. S. Singhal, O.A. Khan, R.A. Bramble Cytomegalovirus disease following liver transplantation an analysis of prophylaxis strategies J Infect 47 2003 104
14. Roche Laboratories: Prevention of CMV disease in heart, kidney, kidney-pancreas, and liver transplantation. Valcyte product information. http://www.rocheusa.com/products/valcyte/pi.pdf. Accessed January 30, 2005.
15. D. Czock, C. Scholle, F.M. Rasche Pharmacokinetics of valganciclovir and ganciclovir in renal impairment Clin Pharmacol Ther 72 2002 142
16. D.M. Olive, M. Simsek, S. Al-Mufti Polymerase chain reaction assay for detection of human cytomegalovirus J Clin Microbiol 27 1989 1238
17. A. Jain, H. Imad, M. Funovits Detection of early antigenemia (pp65) in peripheral blood leukocytes and pre-emptive therapy for cytomegalovirus infection in liver transplant recipients Liver Transplant Surg 5 1999 135
18. N. Rayes, D. Seehofer, C.A. Schmidt Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation Transplantation 72 2001 881
19. J. Torre-Cisneros, J.A. Madueno, C. Herrero Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients Clin Microbiol Infect 8 2002 773
20. P. Orlic, S. Dvornik, S.C. Husnjak pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation Acta Med Croatica 57 2003 49
21. F. Brown, L. Banken, K. Saywell Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV- seropositive volunteers Clin Pharmacokinet 37 1999 167
22. D. Portela, R. Patel, J.J. Larson-Keller OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation J Infect Dis 171 1995 1014
23. M.D. Pescovitz Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients Transpl Infect Dis 1 suppl 1 1999 31
24. M.D. Pescovitz, J. Rabkin, R.M. Merion Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients Antimicrob Agents Chemother 44 2000 2811